IP36-12: Bayesian re-analysis of the NIAGARA trial using reconstructed individual patient data: early event-free survival gains with perioperative durvalumab in muscle-invasive bladder cancer

IP36-12: Bayesian re-analysis of the NIAGARA trial using reconstructed individual patient data: early event-free survival gains with perioperative durvalumab in muscle-invasive bladder cancer

Saturday, May 16, 2026 9:30 AM to 11:30 AM · 1 hr. 59 min. (America/New_York)
147B
Abstract

Log in

See all the content and easy-to-use features by logging in or registering!